Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Colorado for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Colorado only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Colorado (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Stephen Murphy (NPI 1700932316)

Field	Value
Entity Type	Individual
Organization	Stephen Murphy
Address	7111 E Lowry Blvd Ste 200
City	Denver
State	CO
ZIP	80230
Taxonomy	Rheumatology Physician
NPI Enumerated	January 26, 2007

Payer Source	Total Paid
Medicare	$1.4M
Medicaid	$0

Key Findings

This provider is effectively single‑payer: reported lifetime Medicare revenue is $1.4M while Medicaid billing is listed as none below, so all documented public-payer volume and reimbursement in the file comes from Medicare. This concentration means analyses of payor mix, utilization, and risk should treat STEPHEN MURPHY as a Medicare-focused practice.

Revenue is highly concentrated in a small set of biologic/infusion J‑codes: the precomputed top 3 Medicare codes (J0129, J1745, J9312) account for 54.1% of this provider's total Medicare revenue. Specifically, J0129 shows $331.5K revenue (23.1%), J1745 $228.8K revenue (15.9%), and J9312 $217.6K revenue (15.1%), confirming that a majority of Medicare dollars derive from a few injectable biologic agents.

The CPT/HCPCS mix indicates an infusion‑centric rheumatology practice with in‑office administration of biologics and some chemotherapy/infusion services. High-volume J codes for abatacept (J0129), infliximab (J1745 and biosimilar Q5104), rituximab (J9312), golimumab (J1602) and tocilizumab (J3262) point to sustained biologic infusion throughput, while chemotherapy administration codes such as 96413, 96401 and add‑on 96415 show the site also performs antineoplastic infusion services.

Competitive standing is mixed by code: J1745 ranks #118 of 1352 providers nationally (91th percentile), signaling relatively strong national positioning for infliximab administration despite the summary label noting typical volume; J0129 (59th percentile, #498 of 1221) and J9312 (54th percentile, #145 of 317) are more modest, mid‑range participants. Notably, chemotherapy administration code 96413 ranks #470 of 7514 providers (94th percentile) and add‑on 96415 ranks #253 of 4959 providers (95th percentile), both described as notably above typical national volume, which suggests a regional or practice‑level specialization in infusion therapy beyond what many rheumatology peers provide.

Office evaluation and management activity is present but secondary to infusion revenue: 99214 generated $57.8K (4.0% of Medicare revenue) and ranks #33913 of 479517 providers nationally (93th percentile), while 99215 contributed $20.7K (1.4%) and ranks in the 88th percentile. These E/M volumes indicate a steady stream of established patient visits consistent with ongoing management of chronic rheumatologic conditions, but they do not approach the revenue weight of biologic infusions.

The absence of any Medicaid billing on file (none below) means this provider is not participating in state Medicaid billing within the dataset; that limits visibility into low‑income patient access patterns and suggests contracting or payer mix risk if Medicare reimbursement dynamics change. Analysts should treat this profile as Medicare‑dependent for public‑payer exposure and consider commercial payers separately if available.

The provider has an established NPI tenure: enumerated 2007-01-26 (~19 years ago), which supports interpretation that the observed infusion and E/M patterns reflect a long‑standing practice model rather than a short‑term billing anomaly. Longevity may correlate with mature referral relationships and stable patient panels driving repeat biologic and infusion encounters.

There are identifiable code‑level deviations from the overall pattern: 96413 and 96415 are labeled notably above typical national volume, marking them as outliers where this provider exceeds peer infusion activity, whereas J3262 (tocilizumab) ranks #566 of 618 providers (8th percentile) and J3111 ranks in the 17th percentile—both described as typical or unremarkable—indicating relatively low billing for those specific agents compared with peers. These divergences suggest the practice favors particular biologic and infusion agents over others rather than uniform utilization across all rheumatology injectables.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

33 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	9,750	$30	$331.5K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	8,800	$30	$228.8K
J9312	Injection, rituximab, 10 mg	3,400	$60	$217.6K
J1602	Injection, golimumab, 1 mg, for intravenous use	14,500	$10	$145K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	3,910	$30	$109.5K
J0897	Injection, denosumab, 1 mg	6,000	$20	$108K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	580	$110	$62.7K
J3111	Injection, romosozumab-aqqg, 1 mg	7,350	$10	$58.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	620	$90	$57.8K
J3262	Injection, tocilizumab, 1 mg	12,760	$1	$51K

Showing 1–10 of 33

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 33 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Colorado Distribution

Stephen Murphy — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Colorado

Full comparison — all codes billed, vs. state median

33 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	9	30	6,280	$30	$250.4K
J9312	4	10	3,000	$60	$193.6K
J3262	18	20	28,180	$1	$158.6K
J1745	4	40	3,180	$30	$110.6K
J1602	6	20	8,100	$10	$108.9K
J3111	26	40	9,770	$10	$108.3K
J0897	25	140	2,580	$20	$68.8K
Q5104	1	10	1,990	$30	$62.6K
96413	4	140	130	$100	$19.7K
90662	1,112	1,230	40	$70	$15.2K

Showing 1–10 of 33

Related Providers

Other providers that share a Tax Identification Number (TIN) with Stephen Murphy, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Denver Health And Hospital Authority	CO	General Practice Physician	$0	$95M
Denver Health And Hospital Authority	CO	General Acute Care Hospital	$0	$77.1M
Denver Health And Hospital Authority	CO	Federally Qualified Health Center (FQHC)	$0	$68.5M
Denver Health And Hospital Authority	CO	Ambulance	$3.4M	$46.3M
Denver Health And Hospital Authority	CO	Federally Qualified Health Center (FQHC)	$0	$40.3M
Denver Health And Hospital Authority	CO	Federally Qualified Health Center (FQHC)	$0	$29.4M
Denver Health And Hospital Authority	CO	Federally Qualified Health Center (FQHC)	$0	$28.2M
Denver Health And Hospital Authority	CO	Federally Qualified Health Center (FQHC)	$0	$25.5M
Denver Health And Hospital Authority	CO	Federally Qualified Health Center (FQHC)	$0	$17.4M
Denver Health And Hospital Authority	CO	Federally Qualified Health Center (FQHC)	$0	$15.2M

Nearby Providers

Other providers in the same ZIP code as Stephen Murphy, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Total Longterm Care, Inc.	CO	Exclusive Provider Organization	$0	$13M
Denver Health And Hospital Authority	CO	Federally Qualified Health Center (FQHC)	$0	$8.3M
Lowry Pediatrics, PC	CO	Pediatrics Physician	$0	$4.4M
Miriah Teeter	CO	Retina Specialist (Ophthalmology) Physician	$1.9M	$0
Nancy Christmas	CO	Retina Specialist (Ophthalmology) Physician	$1.8M	$0
David Johnson	CO	Specialist	$1.5M	$0
Gregory Barron	CO	Rheumatology Physician	$1.4M	$0
Brian Joondeph	CO	Retina Specialist (Ophthalmology) Physician	$1.4M	$0
Rennie Mccabe	CO	Rheumatology Physician	$1.3M	$0
Vance Bray	CO	Rheumatology Physician	$1.3M	$0

Stephen Murphy — Billing Profile & Reimbursement Data

Sign up for Stephen Murphy — Billing Profile & Reimbursement Data policy alerts

Stephen Murphy — Billing Profile & Reimbursement Data

Sign up for Stephen Murphy — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References